Investors should monitor enrollment progress and safety signals ahead of the late 2026/early 2027 data readout. A successful Phase 1 could de-risk the program and expand Septerna’s valuation premium, especially if SEP-479 demonstrates pharmacodynamic activity and differentiates from injectable PTH therapies.
Price Chart
Executive Summary
Septerna announced the dosing of the first participants in its Phase 1 trial of SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism. Clinical data is expected in late 2026 or early 2027. This marks a key milestone in advancing a potential first-in-class oral therapy for a rare endocrine disorder.
Key Facts
- Septerna has initiated dosing in the Phase 1 clinical trial of SEP-479 for hypoparathyroidism.
- The trial is a single- and multiple-ascending dose study in healthy volunteers, evaluating safety, tolerability, PK, and PD.
- Up to 150 participants will be enrolled; data readout expected in late 2026 or early 2027.
- SEP-479 is a potent oral small molecule agonist targeting the PTH1R receptor, aiming to provide once-daily dosing.
- Preclinical data showed normalization of serum calcium and favorable tolerability in GLP toxicology studies.
Financial Impact
No immediate financial impact; long-term commercial potential hinges on clinical success. Hypoparathyroidism market remains underserved, with current treatments involving daily injections or high-dose supplements.
Risk Factors
- Phase 1 may reveal unexpected safety, PK, or PD findings that could halt development.
- Preclinical results may not translate to humans, particularly in disease-modifying effects.
- Timing delays in trial completion or data readout could dampen investor enthusiasm.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Press Release | $38.51 $38.69 | ▲ +0.47% | ▲ +0.69% | $38.27 (−0.62%) |
Sep 3, 2026 28d ago | 3 | $36.75 $39.55 | ▲ +7.62% | ▲ +8.83% | $38.27 (+4.14%) |
Aug 25, 2026 5w ago | 8-K | $41.30 $37.68 | ▼ −8.77% | ▼ −8.23% | $38.27 (−7.34%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 10, 2026 7w ago | 8-K | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Aug 10, 2026 7w ago | Press Release | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.00 $37.84 | ▲ +11.29% | ▲ +10.36% | $38.27 (+12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access